Due to the unique characteristics of drug development, usually only one active compound would be selected from tens of thousands of candidates for use for medicinal purposes.
Amidst the “heat” of such buffooneries looms a fact that many of the participants do not know how to protect their intangible assets with an IP “combination style.”
On debated issue over proper application of Article 33 of Patent Law, the article tries to compare with examination practices in other countries, comment on views of judicial decisions.
